Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.60 |
| ▸ | GOT1 | P17174 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22699913 | 0.88 | STING1 (0.46) | STING1PRKCBAURKBHDAC1HDAC3 | |
| SCHEMBL31744663 | 0.88 | STING1 (0.67) | STING1GOT1TRPV1IGF1RMET | |
| SCHEMBL22700027 | 0.83 | CNR1 (0.49) | STING1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL22700033 | 0.82 | STING1 (0.41) | STING1AURKBHDAC1HDAC3HDAC4 | |
| SCHEMBL25120717 | 0.82 | STING1 (0.43) | STING1TRPV1 | |
| SCHEMBL25120783 | 0.82 | SNCA (0.43) | STING1GOT1AURKBHDAC1 | |
| SCHEMBL25120782 | 0.80 | STING1 (0.60) | STING1CFTR | |
| SCHEMBL22700056 | 0.78 | STING1 (0.41) | STING1PTGS2CFTR | |
| SCHEMBL22828628 | 0.78 | HDAC1 (0.38) | STING1AURKBHDAC1HDAC3HDAC4 | |
| SCHEMBL22700029 | 0.76 | STING1 (0.59) | STING1GOT1TRPV1IGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2022140387-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140397-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140410-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140403-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | STING1 1/4885GOT1 176/4885TRPV1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.